Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5737001 | 0.99 | SLC10A2 (0.79) | SLC10A2 | |
| SCHEMBL5734702 | 0.99 | SLC10A2 (0.79) | SLC10A2 | |
| SCHEMBL5738436 | 0.93 | SLC10A2 (0.79) | SLC10A2 | |
| SCHEMBL5736983 | 0.92 | SLC10A2 (0.70) | SLC10A2 | |
| SCHEMBL5735279 | 0.92 | SLC10A2 (0.70) | SLC10A2 | |
| SCHEMBL5736416 | 0.90 | SLC10A2 (0.74) | SLC10A2 | |
| SCHEMBL5737649 | 0.88 | SLC10A2 (0.68) | SLC10A2 | |
| SCHEMBL5738089 | 0.88 | SLC10A2 (0.67) | SLC10A2 | |
| SCHEMBL14682029 | 0.86 | SLC10A2 (0.71) | SLC10A2 | |
| SCHEMBL5736175 | 0.86 | SLC10A2 (0.62) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345932-B1 | DIPHENYL AZETIDINONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THEIR USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-10-18 | — | — | EP | disclosed |
| US-6498156-B2 | TREATING HYPERLIPIDEMIA, ARTERIOSCLEROSIS AND HYPERCHOLESTEROLEMIA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-24 | — | — | US | disclosed |
| US-20020128252-A1 | Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128252-A1 | Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB6, NDUFB7 | SLC10A2 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.